0001021771-24-000079.txt : 20240320
0001021771-24-000079.hdr.sgml : 20240320
20240320163857
ACCESSION NUMBER: 0001021771-24-000079
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240318
FILED AS OF DATE: 20240320
DATE AS OF CHANGE: 20240320
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Silva Francisco
CENTRAL INDEX KEY: 0001527241
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37603
FILM NUMBER: 24768289
MAIL ADDRESS:
STREET 1: STEM CELL ASSURANCE, INC.
STREET 2: 555 HERITAGE DRIVE
CITY: JUPITER
STATE: FL
ZIP: 33458
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BioRestorative Therapies, Inc.
CENTRAL INDEX KEY: 0001505497
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 301341024
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 40 MARCUS DRIVE
CITY: MELVILLE
STATE: NY
ZIP: 11747
BUSINESS PHONE: (631) 760-8100
MAIL ADDRESS:
STREET 1: 40 MARCUS DRIVE
CITY: MELVILLE
STATE: NY
ZIP: 11747
FORMER COMPANY:
FORMER CONFORMED NAME: Stem Cell Assurance, Inc.
DATE OF NAME CHANGE: 20101110
4
1
form4.xml
X0508
4
2024-03-18
0001505497
BioRestorative Therapies, Inc.
BRTX
0001527241
Silva Francisco
C/O BIORESTORATIVE THERAPIES, INC.
40 MARCUS DRIVE
MELVILLE
NY
11747
true
true
VP of Research and Development
false
Common Stock
2024-03-18
4
F
0
17193
1.39
D
147451
D
Common Stock
12136
I
IRA
Stock Option
3000
2024-10-23
Common Stock
9
9
D
Stock Option
3000
2025-09-04
Common Stock
6
6
D
Stock Option
3000
2026-06-10
Common Stock
15
15
D
Stock Option
3000
2027-07-12
Common Stock
20
20
D
Stock Option
3000
2028-10-29
Common Stock
25
25
D
Stock Option
5.08
2031-03-18
Common Stock
293479
293479
D
Stock Option
5.08
2031-11-04
Common Stock
42059
42059
D
Stock Option
2.91
2033-02-17
Common Stock
106762
106762
D
Stock Option
1.45
2034-02-13
Common Stock
394737
394737
D
Shares were withheld from vested stock grant to pay the associated withholding taxes.
The option is currently exercisable.
The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 and 21,029 shares in eight nearly equal quarterly installments beginning November 4, 2022 and continuing every three months thereafter until fully vested.
The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested.
The option vests and becomes exercisable to the extent of 197,369 shares on February 13, 2024 and 197,368 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested.
/s/ Franisco Silva
2024-03-20